Skip to main content

Table 2 MOS-sleep and EQ-5D questionnaire scores by treatment group

From: Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors

  Pregabalin Usual care p between groups
N= 486 N= 239
Baseline Final Change (95% CI) Baseline Final Change (95% CI) Baseline Final a
MOS-sleep scale, mean (SD)         
  Sleep disturbance (0–100) 58.1 (18.9) 27.1 (17.5) −29.3 (−31.1, −27.4)** 50.1 (20.7) 32.0 (21.2) −22.4 (−24.9, −19.9)** <0.001 <0.001
  Snoring while sleep (0–100) 32.5 (29.0) 23.9 (26.0) −7.1 (−9.0, −5.2)** 30.2 (30.3) 24.7 (26.9) −4.8 (−7.4, −2.2)** 0.175 0.142
  Awakening short of breath (0–100) 39.9 (22.8) 17.7 (19.6) −20.3 (−22.2, −18.4)** 30.6 (23.9) 20.9 (22.9) −13.2 (−15.7, −10.6)** <0.001 <0.001
  Optimal sleep (0–1) 0.19 (0.39) 0.65 (0.48) 0.46 (0.41, 0.51)** 0.26 (0.44) 0.61 (0.49) 0.41 (0.34, 0.48)** <0.050 0.268
  Sleep quality (0–100) 28.3 (19.7) 61.3 (24.0) 31.1 (28.7, 33.5)** 35.7 (22.6) 55.1 (26.1) 22.8 (19.5, 26.1)** <0.001 <0.001
  Daytime sleepiness (0–100) 38.6 (18.6) 21.6 (15.9) −16.0 (−17.6, −14.4)** 33.7 (19.3) 23.6 (18.5) −12.5 (−14.6, −10.3)** <0.001 0.006
  Sleep hours per night (0–24) 5.53 (1.25) 6.91 (1.05) 1.27 (1.16, 1.38)** 5.95 (1.53) 6.91 (1.13) 1.14 (0.98, 1.31)** <0.001 0.170
  General index sleep problems (0–100) 55.0 (15.0) 27.0 (16.0) −26.4 (−28.1, −24.7)** 47.5 (16.8) 31.2 (19.1) −19.6 (−22.0, −17.3)** <0.001 <0.001
EQ-5D questionnaireb         
  Mobility 1.40 (0.50) 1.22 (0.44) −0.17 (−0.21, −0.13)* 1.29 (0.50) 1.17 (0.39) −0.17 (−0.22, −0.12)* 0.002 0.922
[39.4] [21.4]   [27.1] [17.0]   <0.001 0.375
  Personal care 1.26 (0.45) 1.09 (0.29) −0.15 (−0.18, −0.12)* 1.19 (0.42) 1.12 (0.36) −0.12 (−0.16, −0.08)* 0.027 0.174
[26.0] [8.7]   [18.4] [10.3]   0.032 0.196
  Activities of daily living 2.14 (0.50) 1.56 (0.54) −0.52 (−0.58, −0.47)** 1.88 (0.49) 1.59 (0.58) −0.43 (−0.51, −0.36)** <0.001 0.047
[93.3] [53.3]   [81.5] [54.7]   <0.001 0.221
  Pain/discomfort 2.11 (0.63) 1.57 (0.60) −0.51 (−0.56, −0.45)** 1.90 (0.63) 1.58 (0.62) −0.42 (−0.49, −0.35)** <0.001 0.043
[85.4] [51.5]   [74.6] [50.8]   <0.001 0.789
  Anxiety/depression 2.52 (0.52) 1.54 (0.58) −0.94 (−1.00, −0.64)** 2.37 (0.57) 1.75 (0.61) −0.72 (−0.80, −0.64)** 0.001 <0.001
[98.8] [50.0]   [95.8] [65.7]   0.002 <0.001
Self-valuation quality of life (EQ-VAS; 0–100) 42.7 (15.5) 70.0 (17.3) 26.4 (24.7, 28.1)** 48.9 (15.7) 65.5 (18.3) 19.4 (17.1, 21.6)** <0.001 <0.001
Health status (utility index; 0–1) 0.40 (0.30) 0.78 (0.25) 0.36 (0.34, 0.38)** 0.53 (0.31) 0.75 (0.28) 0.29 (0.26, 0.33)** <0.001 <0.001
  1. Values are expressed as mean (SD, standard deviation) or 95% confidence intervals (CI) unless otherwise stated.
  2. aComparison of the change from baseline between the two groups adjusted by baseline values and sex and age.
  3. bThe percentage of patients who still have problems (sum of categories 2 and 3) for each EQ-5D component are expressed within brackets.
  4. p < 0.05, *p < 0.01, **p < 0.001 vs. baseline values.